CE marking for the Episealer ® Talus implant expected for Episurf Medical
Episurf Medical (NASDAQ: EPIS B) announces that today, the company has been informed by its notified body that the review process for obtaining CE mark for the ankle implant Episealer® Talus has been concluded and that the final formal process for issuing the CE-certificate is expected to be completed within 2 weeks. The implant is intended for osteochondral lesions of the talar dome of the ankle joint. The new ankle implant is supplied together with a kit of surgical tools, and the devices are based on the same technology platform as the company’s Episealer® knee devices, with an